Huang Hui, Meegalla Sanath K, Lanter James C, Winters Michael P, Zhao Shuyuan, Littrell James, Qi Jenson, Rady Brian, Lee Paul S, Liu Jianying, Martin Tonya, Lam Wing W, Xu Fran, Lim Heng Keang, Wilde Thomas, Silva Jose, Otieno Monicah, Pocai Alessandro, Player Mark R
Departments of Medicinal Chemistry, Cardiovascular & Metabolism in Vitro Biology, Cardiovascular & Metabolism in Vivo Pharmacology, andPreclinical Drug Safety, Janssen Research & Development, Welsh and McKean Roads,Spring House, Pennsylvania 19477-0776, United States.
ACS Med Chem Lett. 2018 Dec 3;10(1):16-21. doi: 10.1021/acsmedchemlett.8b00444. eCollection 2019 Jan 10.
GPR40 is a G-protein-coupled receptor which mediates fatty acid-induced glucose-stimulated insulin secretion from pancreatic beta cells and incretion release from enteroendocrine cells of the small intestine. GPR40 full agonists exhibit superior glucose lowering compared to partial agonists in preclinical species due to increased insulin and GLP-1 secretion, with the added benefit of promoting weight loss. In our search for potent GPR40 full agonists, we discovered a superagonist which displayed excellent in vitro potency and superior efficacy in the Gα-mediated signaling pathway. Most synthetic GPR40 agonists have a carboxylic acid headgroup, which may cause idiosyncratic toxicities, including drug-induced-liver-injury (DILI). With a methyl group and a fluorine atom substituted at the α-C of the carboxylic acid group, is not only highly efficacious in lowering glucose and body weight in rodent models but also has a low DILI risk due to its stable acylglucuronide metabolite.
GPR40是一种G蛋白偶联受体,它介导脂肪酸诱导的胰腺β细胞葡萄糖刺激的胰岛素分泌以及小肠肠内分泌细胞的内分泌释放。在临床前物种中,由于胰岛素和胰高血糖素样肽-1(GLP-1)分泌增加,GPR40完全激动剂与部分激动剂相比具有更好的降糖效果,还有促进体重减轻的额外益处。在寻找强效GPR40完全激动剂的过程中,我们发现了一种超级激动剂,它在体外具有出色的效力,并且在Gα介导的信号通路中具有卓越的功效。大多数合成的GPR40激动剂都有一个羧酸头部基团,这可能会导致特异质性毒性,包括药物性肝损伤(DILI)。通过在羧酸基团的α-C位上取代一个甲基和一个氟原子,[具体化合物名称未给出]不仅在啮齿动物模型中降低血糖和体重方面非常有效,而且由于其稳定的酰基葡萄糖醛酸代谢产物,其DILI风险较低。